Department of Radiation Oncology, University of Lübeck, Lübeck, Germany;
Department of Radiation Oncology, University of Lübeck, Lübeck, Germany.
Anticancer Res. 2023 Feb;43(2):801-807. doi: 10.21873/anticanres.16221.
BACKGROUND/AIM: Very elderly patients irradiated for bone metastases likely benefit from individualized treatments. A specific survival score was created for this group and compared to existing instruments.
Ninety-six patients aged 80+ irradiated for bone metastases were retrospectively evaluated. Dose-fractionation regimen plus twelve characteristics were evaluated for survival.
In the Cox regression model, performance status and tumor type were significant and used for the score, which included three groups (5-7, 8-12, and 14 points) with 6-month survival rates of 15%, 52%, and 90%. Positive predictive values (PPVs) regarding death ≤6 months were 85% (new score), 100% (previous 65+ score), and 84% (previous score for any age). The new instrument and the 65+ score were also very accurate regarding survival. Since PPV regarding death was calculated from only four patients for the 65+ score, this PPV may be less conclusive than that for the new instrument.
The new score appears useful for patients aged 80+ irradiated for bone metastases.
背景/目的：对于接受放射性治疗骨转移的非常高龄患者，个体化治疗可能会带来益处。为此人群创建了一个特定的生存评分，并与现有工具进行了比较。
回顾性评估了 96 名年龄在 80 岁以上接受放射性治疗骨转移的患者。评估了剂量分割方案加 12 项特征与生存之间的关系。
在 Cox 回归模型中，表现状态和肿瘤类型是显著的，并用于评分，评分包括三组（5-7、8-12 和 14 分），6 个月生存率分别为 15%、52%和 90%。死亡≤6 个月的阳性预测值（PPV）分别为 85%（新评分）、100%（65+ 评分）和 84%（任何年龄的评分）。新工具和 65+评分在生存方面也非常准确。由于 65+评分中只有 4 名患者的死亡进行了计算，因此该评分的 PPV 可能不如新工具的结论明确。
新的评分似乎对接受放射性治疗骨转移的 80 岁以上患者有用。
